Neurology:取栓后24h血压目标值,5000例患者的数据分析

2022-02-15 杨中华 “ 脑血管病及重症文献导读”公众号

在最近一项观察性队列研究的配对荟萃分析中,患者的预后与EVT术后血压水平的关系比术前或围手术期血压更密切。同样,在各自的时间间隔内,收缩压的相关性比舒张压的相关性更强。

尽管血管内血栓切除术endovascular thrombectomy,EVT)是迄今为止唯一可用于改善由颅内大血管闭塞(large vessel occlusion,LVO)引起的急性缺血性卒中(acute ischemic stroke,AIS)发病率和死亡率的手术治疗方法,在血管内手术结束后成功再灌注的患者中,约有一半死亡或永久残疾。

在接受急性再灌注治疗的患者中,EVT后的血压(BP)管理可能是改善神经功能预后的一个变量。对于接受EVT的LVO患者,指导BP管理的数据有限,对于EVT手术之前、期间和之后的最佳BP目标,也没有明确的共识。尽管目前的指南建议在EVT期间和EVT后的前24小时内,收缩压目标为<=180毫米汞柱,舒张压105毫米汞柱,他们还强调了缺乏证实这一立场的随机试验。这些血压目标值来自于静脉溶栓的临床试验,静脉溶栓的成功再灌注的可能性较小,而EVT时可以实时确认动脉是否再通,所以这些血压目标值可能不适合EVT。此外,在真实世界中,不同中心对EVT后的BP目标值存在很大差异。

在最近一项观察性队列研究的配对荟萃分析中,患者的预后与EVT术后血压水平的关系比术前或围手术期血压更密切。同样,在各自的时间间隔内,收缩压的相关性比舒张压的相关性更强。

2022年1月来自加拿大的Aristeidis H. Katsanos等在Neurology上公布了他们的研究结果,该研究对已发表的观察性研究进行了个体患者数据的荟萃分析(Individual Patient Data Meta-analysis,IPD-MA),进一步评估了前循环LVO的AIS患者EVT后血压水平与临床结局之间的相关性。

方法:主要纳入标准包括,年龄大于18岁的AIS患者,接受了成功或失败的EVT治疗,并且提供了EVT手术结束后的个体或平均24小时收缩压值。

共纳入7项研究的5874名患者(平均年龄69岁+-14;50%为女性;入院时NIHSS中位数16分)。在EVT结束后的前24小时内,平均收缩压水平每增加10毫米汞柱与较低几率的功能改善有关(未经调整的共同优势比[OR]0.82,95%可信区间[CI]0.80–0.85;调整共同优势比0.88,95%可信区间0.84–0.93),和较低比例的mRS≤2有关(未调整OR 0.82,95%可信区间0.79-0.85;调整OR 0.87,95%可信区间0.82-0.93),以及和较高比例的3个月时全因死亡率有关(未调整OR 1.18,95%可信区间1.13-1.24;调整OR 1.15,95%可信区间1.06-1.23)。

较高水平的24小时平均收缩压也与EVT后早期神经功能恶化(未经调整的OR 1.14,95%可信区间1.07-1.21;经调整的OR 1.14,95%可信区间1.03-1.24),以及症状性颅内出血(未经调整的OR 1.20,95%可信区间1.09-1.29;经调整的OR 1.20,95%可信区间1.03-1.38)的可能性增加有关。EVT的再通状态对上述关系没有影响。

最终作者认为,EVT术后前24小时内平均收缩压水平升高与症状性颅内出血、早期神经功能恶化、3个月死亡率和3个月功能转归恶化的几率增加独立相关。

译者注:取栓第一个24h内的血压管理存在很大争论,不同研究得到了不同甚至是相反的结果,还需要设计精良的随机对照研究回答这个问题。

 

原始出处:

Aristeidis H. Katsanos, Konark Malhotra, Niaz Ahmed, et al. Blood Pressure After Endovascular Thrombectomy and Outcomes in Patients With Acute Ischemic Stroke: An Individual Patient Data Meta-analysis. Neurology. 2022 Jan 18;98(3):e291-e301. doi: 10.1212/WNL.0000000000013049. Epub 2021 Nov 12.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078150, encodeId=2ea520e8150fa, content=<a href='/topic/show?id=86ec889615b' target=_blank style='color:#2F92EE;'>#血压目标值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88961, encryptionId=86ec889615b, topicName=血压目标值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 10:53:31 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479115, encodeId=aeee14e911587, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Wed Feb 16 02:53:31 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193615, encodeId=692c11936158b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXDxxEaeS1vDVInBReSAGZ5picqGbrabFNqbVhbZNiabqxZ097HuW1nxBuyYGnibxibZuR6RQBJ4Ujg/132, createdBy=56e75105932, createdName=ms3596413418274757, createdTime=Tue Feb 15 14:26:51 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001732, encodeId=d8852001e32ce, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jun 09 22:53:31 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078150, encodeId=2ea520e8150fa, content=<a href='/topic/show?id=86ec889615b' target=_blank style='color:#2F92EE;'>#血压目标值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88961, encryptionId=86ec889615b, topicName=血压目标值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 10:53:31 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479115, encodeId=aeee14e911587, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Wed Feb 16 02:53:31 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193615, encodeId=692c11936158b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXDxxEaeS1vDVInBReSAGZ5picqGbrabFNqbVhbZNiabqxZ097HuW1nxBuyYGnibxibZuR6RQBJ4Ujg/132, createdBy=56e75105932, createdName=ms3596413418274757, createdTime=Tue Feb 15 14:26:51 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001732, encodeId=d8852001e32ce, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jun 09 22:53:31 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078150, encodeId=2ea520e8150fa, content=<a href='/topic/show?id=86ec889615b' target=_blank style='color:#2F92EE;'>#血压目标值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88961, encryptionId=86ec889615b, topicName=血压目标值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 10:53:31 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479115, encodeId=aeee14e911587, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Wed Feb 16 02:53:31 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193615, encodeId=692c11936158b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXDxxEaeS1vDVInBReSAGZ5picqGbrabFNqbVhbZNiabqxZ097HuW1nxBuyYGnibxibZuR6RQBJ4Ujg/132, createdBy=56e75105932, createdName=ms3596413418274757, createdTime=Tue Feb 15 14:26:51 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001732, encodeId=d8852001e32ce, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jun 09 22:53:31 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-02-15 ms3596413418274757

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2078150, encodeId=2ea520e8150fa, content=<a href='/topic/show?id=86ec889615b' target=_blank style='color:#2F92EE;'>#血压目标值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88961, encryptionId=86ec889615b, topicName=血压目标值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 10:53:31 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479115, encodeId=aeee14e911587, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Wed Feb 16 02:53:31 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193615, encodeId=692c11936158b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXDxxEaeS1vDVInBReSAGZ5picqGbrabFNqbVhbZNiabqxZ097HuW1nxBuyYGnibxibZuR6RQBJ4Ujg/132, createdBy=56e75105932, createdName=ms3596413418274757, createdTime=Tue Feb 15 14:26:51 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001732, encodeId=d8852001e32ce, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jun 09 22:53:31 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-06-09 yinhl1978

相关资讯

Neurology:血压变异越大,认知减退越快

血压变异越大,认知减退越快

高血压患者夜间血压管理的机遇与挑战

血压波动是人体正常生理反应,但血压的异常波动与人体的多种疾病状况密切相关。在血压波动中,夜间血压的异常升高与心血管不良结局更加相关。

Circulation:血压的性别差异与心血管预后相关,女性血压的“正常”范围低于男性

男性相比,女性心血管疾病的风险增加始于较低的收缩压阈值

AHA 2020丨从SPRINT全新亚组结果探寻改善我国血压管理的策略和方向

高血压作为心血管疾病的首要危险因素,是所有心血管领域会议永恒的重点话题,降压治疗方面的进展备受广大心血管医师关注。

Alzheimers Dementia: 收缩压变异越大,痴呆风险越高

收缩压变异越大,痴呆风险越高

Lancet子刊:老年女性收缩压低于120 mmHg,更有益大脑健康,减少认知障碍!

将老年女性高血压患者的收缩压治疗目标值定为低于120 mmHg不仅相对安全,且对其认知健康具有重要保护作用。研究结果支持老年女性高血压患者进行强化血压管理,即收缩压降压目标需低于120 mmHg(或脉